Kyoto, Japan

Kaoru Kurose

This inventor holds 3 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignee: Arkray, Inc.. Active years: 2014-2016.

USPTO Granted Patents = 3 

% Patents Active = 66.7

 

Average Co-Inventor Count = 1.5

ph-index = 1


Company Filing History:


Years Active: 2014-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kaoru Kurose: Innovator in Mutation Detection Technologies

Introduction

Kaoru Kurose is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of mutation detection, particularly in relation to genetic research and drug efficacy evaluation. With a total of 3 patents to his name, Kurose's work has the potential to impact medical diagnostics and treatment strategies.

Latest Patents

Kurose's latest patents include a mutation detection probe and method, as well as a method for evaluating drug efficacy. His invention provides a probe for detecting mutations in the ALK gene, utilizing fluorescently labeled oligonucleotides. Additionally, he has developed a method for detecting mutations at IL28B and ITPA, which involves probes for identifying polymorphisms in these genes.

Career Highlights

Kurose is currently associated with Arkray, Inc., a company known for its innovative solutions in the healthcare sector. His work at Arkray has allowed him to focus on advancing technologies that enhance mutation detection and improve patient outcomes.

Collaborations

Kurose collaborates with notable colleagues, including Toshiya Hosomi and Aki Iguchi. Their combined expertise contributes to the development of cutting-edge technologies in genetic research.

Conclusion

Kaoru Kurose's contributions to mutation detection technologies exemplify the importance of innovation in the medical field. His patents and ongoing work continue to pave the way for advancements in genetic diagnostics and treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…